Get the Stockscreener App
249.46
0.54%
-1.36
After Hours:
249.53
0.07
+0.03%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $249.46, with a volume of 3.99M.
It is down -0.54% in the last 24 hours and up +1.91% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$250.82
Open:
$250.6
24h Volume:
3.99M
Relative Volume:
0.62
Market Cap:
$440.83B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
123.04
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+1.39%
1M Performance:
+1.91%
6M Performance:
+7.76%
1Y Performance:
+21.88%
1-Day Range:
$247.68
$250.61
1-Week Range:
$244.03
$255.29
52-Week Range:
$190.75
$267.47
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
249.46 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,180.16 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.35 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
135.84 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.88 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Defends Its Turf, But Leaves One Big Question Open - Trefis
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026? - TradingView
AbbVie (NYSE:ABBV): Is More Momentum Ahead? - Kalkine Media
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
Gateway Investment Advisers LLC Sells 13,696 Shares of AbbVie Inc. $ABBV - MarketBeat
Clarity Financial LLC Has $50.02 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? - Yahoo Finance
Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth? - Yahoo Finance
Wolfe Research Issues Rare Double Upgrade for Biogen and AbbVie, Setting $300 Targets - finance.biggo.com
Why Is AbbVie (NYSE:ABBV) In Focus as Immunology Franchise Draws Attention Worth Watching? - kalkinemedia.com
ABBV Upgraded by Wolfe Research -- Price Target Raised to $300 - GuruFocus
Could Why Is AbbVie (NYSE:ABBV) in View as the Broad Market Nears Records Stay in Focus? - Kalkine Media
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation - Yahoo Finance
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More - Yahoo Finance
Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300 - marketscreener.com
AbbVie Inc. $ABBV Shares Acquired by Mission Wealth Management LP - MarketBeat
Moody Lynn Lieberson & Walker LLC Has $42.52 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Harmony Asset Management LLC Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Riverchase Wealth Management LLC Buys New Position in AbbVie Inc. $ABBV - MarketBeat
How ABBV Stock Moved Away From Its Peer Group - Trefis
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield - Yahoo Finance
Prediction: AbbVie Will End The Year at This Price - AOL.com
AbbVie Inc. $ABBV Shares Bought by Wedge Capital Management L L P NC - MarketBeat
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal - Investing.com
Cardinal Capital Management Inc. Buys 21,206 Shares of AbbVie Inc. $ABBV - MarketBeat
GODSEY & GIBB, INC's AbbVie Inc(ABBV) Holding History - GuruFocus
VIP Health Care Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment - Yahoo Finance
AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There? - Yahoo Finance
Why Is AbbVie (NYSE:ABBV) the Healthcare Name Riding Its Immunology Momentum? - Kalkine Media
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
ABBV Maintained by BNP Paribas -- Price Target Raised to $247 - GuruFocus
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? - AOL.com
BNP Paribas Exane Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock - MarketBeat
Integrity Advisory Solutions, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating - marketscreener.com
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices - Yahoo! Finance Canada
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? - Yahoo Finance
AbbVie Inc. $ABBV Position Cut by Handelsbanken Fonder AB - MarketBeat
KMG Fiduciary Partners LLC Cuts Stake in AbbVie Inc. $ABBV - MarketBeat
Carolina Wealth Advisors LLC Purchases 7,626 Shares of AbbVie Inc. $ABBV - MarketBeat
Global drugmakers invest billions to boost US presence - Reuters
Osterweis Growth & Income Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie, Novartis Seek Block Illinois 340B Drug Discount Law - Law360
Pharma giants, including AbbVie, sue to block Illinois drug discount law - Crain's Chicago Business
AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use - Yahoo Finance
AbbVie, Novartis Sue Illinois Over Hospital Drug Pharmacy Law - Bloomberg Law News
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings? - The Motley Fool
Apogee reports $85.9 million Q2 loss as AbbVie deal advances - Quiver Quantitative
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):